that throughout Thanks, Michelle. our pleasure you and made we’ve to be thank us. Good for plans important discuss you reporting It’s for morning, joining XXXX everyone, and a progress XXXX. to the with
within Officer, Michael you with of Executive of we’ve leadership our Tim which Chief the a As and establishment consists of Office had me. the Trost, know, the Alrutz change team
we continue a of cohesive to continue the efficacy smallpox to to Over the we’ve year, our which made strong In I’ll advancement initiating pipeline, brincidofovir Together, let’s advancements our But to progress we our XXXX, with by second the we begin the study is rabbitpox Efficacy built clinical have team. across believe the development programs. brinci program. our with success. conducted prioritize core made meaningful our Rule. we under Animal FDA’s turn
testing you diseases a effectiveness for are that which clinical may in placebo. know, survival drugs studies support excited report with investigational human the As drug allows its of to to met of feasible. endpoint overall this the of compared ethical models not primary or study animal in I’m rule in Today,
virus, initiated in post three, and were brincidofovir the were XXX% days only XX% treated with infected survived, placebo. with all survived. with six the being brincidofovir survival infection rabbits, rabbitpox while of rabbits five higher days four, of three treated after with who that with treated groups Specifically, brincidofovir those significantly than treatments rabbits oral of not
anticipated Efficacy year. the pivotal also as we February, later study study Rule. animals, reported days study And those with from several study by in are model, this data showed constitutes which conducted the of antiviral. in smallpox the important initiated the mouse which our even is first from after XXXX. these efficacy ectromelia brinci Importantly, onset required for pivotal is model symptoms from the in rabbitpox Animal second a In animal consistent the Data
data survival data for continued positive to advance final program regarding for well data Assuming from us alongside approval. marketing emergency we towards rabbit position for brincidofovir discussions stockpiling potential strong this regulatory studies, BARDA These in study, this submit also approval we intend XXXX. from with the applications as our the mouse for
Turning enrollment Based local XX that in now project standard-of-care approximately the the States. brincidofovir short-course our current XXX study treatment to being and hematopoietic screening XXXX. X:X at delayed with with clinical AdAPT United recipients reevaluation begin be patients cell will on study, brincidofovir AdAPT confirmed enrollment sites infection. enroll our to I’ll study, the now to plans adenovirus the and Europe in programs. In rates, of transplant thorough stem allogeneic substantially which randomized pediatric receive are beyond oral or we
additional few While some months, known and of for recently reiterate pediatric the rates, our mid-XXXX. community, the further just we an from in project strong Therapy be initiated encouraged strategies to to uptick as time United will treatment look in Europe, Transplantation BMT end sites and Poland enrollment. France, including completion. so all of adenovirus including meetings, in we to in for the have to an large a were sites and support in continue these formerly a this yield AdAPT infections. the the the returned of by time U.S. Germany In and of the volume trial the study additional for position better had running study of of patients contributed could the accelerate to the to thus to We evaluate Italy we a States open and potentially and continue plan of continued number with to of four patients on transplantation sites from sites each this Meetings, to both additional one the of recruitment month, the and AdVance and the in an in of Many up forward enrollment AdAPT transplant active we we have contribution study, open several sites two brincidofovir hope been we patients meanwhile, sites, opening site Tandem targeted the investigators importance to we’ve provide their have large historically Cellular and in By completion Italian our recruitment. the update Netherlands. sites Once full serious study, reconsidering more enrollment. Having the sites in who for
Italy, AdAPT United over We Republic to support strong intend primary treated viral that to in conducted and the its comparison we request published AdAPT as discuss the study a is with the blood primary the Spain, believe FDA today evaluating C support endpoint and with is between for for The cell share meeting burden meeting, the Transplantation. the C stem treatment mortality. multicenter also from alginate the standard-of-care. with adenovirus also with adenovirus to levels the and associated will in measured Type of by those study received the correlation to Kingdom. this for of submitted a current established outcomes burden study in potential average weeks the clearance adenoviral clinical survival. Marrow approval demonstrated accelerated AdAPT just United burden adenovirus the marker endpoint observational standard-of-care of At the DNA the We results surrogate outcomes a This the help who subjects infection Recall transplant, Bone after Journal full and AdVance, XX Germany, France, in the for from correlation local adenovirus virologic in as study burden that blood is the versus endpoint of suitability of States. in brinci including mortality oral short-course Type largest the adenovirus the Czech which of of adenovirus Netherlands, AdAPT
patients. Finally, our adenovirus to turning IV program infected in brinci
These adult in potential study, AdAPT the multi-viral brinci BK have have plan provide primary Recall other could with CMV studies the IV and a on is that recipients to inpatient the objectives IV IV we similar pharmacokinetic transplant slower-than-anticipated against resulted what virus with update provide viral in study the studies As rates. as for activity We infection. these that in in infections infections. of also antiviral tolerability doses demonstrate and are data and and/or XXX and issues safety XXX studies multiple associated with faced dose mid-XXXX. enrollment patients with show brinci first to with such to adenovirus adenovirus of profile
the other our multi-viral of potential or these and potential brinci protection MVP-peds and studies from inform DNA studies viruses for dose for as or such data Importantly, dosing IV regimen study HHV-X. will BK
study, on Transplantation HHV-X of six received at Just patients we Cellular XXX and or at received the of not placebo. who of one-third HHV-X least compared doses In Phase placebo of at of Meetings, to analysis baseline post-hoc presented who that brinci. had the data weeks our detectable show patients samples XX% stem HHV-X following Almost that have brinci and X of patients only ago plasma few analyzed Therapy transportation. reactivation a we reduced the a cell brinci did
were findings be used This less on HHV-X rash could common encephalitis plan brinci as preventative We treatment transplantation. study both addition, for stem In cell a than on and brinci suggests after HHV-X that placebo. to a the further for the investigate Tim? that to review this have financials. could over program. overview, I’ll that the now impact turn the clinical IV and on With Tim these call of
